



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
55099-A-PCT-
US/JPW/AJM/AJDSerial No.
09/664,485INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicant(s)
Ilya TrakhtFiling Date
September 18, 2000Group Art Unit
1648

U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No.	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Brodin T., Olsson L., Sjorgen H. (1983) Cloning of human hybridoma, myeloma, and lymphoma cell lines using enriched human monocytes as feeder layer, J. Immunol. Meth. 60: 1-7;
	2	Goldman-Leikin, R.E., Salawen, H.R., Herst, C.V., Variakojis, D., Bian, M.L., Le Beau, M.M., Selvanayagen, P., Marder R., Anderson, R., Weitzman, S., Rosen, S.T. (1989) Characterization of a novel myeloma line MM-1, J. Lab. Clin. Med. 113: 335-345;
	3	Kozbor, D., Roder, J.C. (1981) Requirements for the establishment of high titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique, J. Immunol. 127: 1275-1280;
	4	Kozbor, D., Tripputi, P., Roder, J.C., Croce, C.M. (1984) A human hybrid myeloma for production of human monoclonal antibodies, J. Immunol. 133: 3001-3005
	5	Levy, R., Miller, R.A. (1983) Tumor therapy with monoclonal antibodies, Fed. Proc. 42: 2650-2656;
	6	Nilsson, K., Ponten, J. (1975) Classification and biological nature of established human hematopoietic cell lines, Int. J. Cancer 15: 321-341;
	7	Oestberg, L., Pursch, E. (1983) Human x (mouse x human) hybridomas stably producing human antibodies, Hybridoma 2: 361-367;
	8	Posner, M.R., Schlossman, S.F., Lazarus, H. (1983) Novel approach to the construction of human "myeloma analogues" for the production of human monoclonal antibodies, Hybridoma 2: 369-381;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 55099-A-PCT- US/JPW/AJM/AJD		Serial No. 09/664,485						
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant(s) Ilya Trakht								
				Filing Date September 18, 2000		Group Art Unit 1648						
U.S. PATENT DOCUMENTS												
Examiner Initials	Exh. No.	Document Number						Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS												
		Document Number						Date	Country	Class	Subclass	Translation
												Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
	9	Reading, C.L. (1982) Theory and methods for immunization in culture and monoclonal antibody production, J. Immunol. 53: 261-291;										
	10	Raison, R.L., Walker, K.Z., Halnan, C.R.E., Briscoe, D., Basten, A. (1982) Loss of secretion in mouse-human hybrids need not be due to the loss of a structural gene, J. Exp. Med. 156: 1380-1389;										
	11	Teng, N.N.H., Lam, K.S., Riera, F.C., Kaplan, H.S. (1993) Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production, Proc. Natl. Acad. Sci. (U.S.A.) 80: 7308-7311; and										
	12	Weiss, M.C., Green, H. (1967) Human mouse hybrid cell lines containing partial complements of human chromosomes and functioning human genes, Proc. Natl. Acad. Sci. (U.S.A.) 58: 1104-1111.										
EXAMINER					DATE CONSIDERED							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												